Bavarian Nordic (OTCMKTS:BVNRY) Releases Quarterly Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) announced its quarterly earnings results on Friday. The company reported $0.46 EPS for the quarter, Zacks reports. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.

Bavarian Nordic Stock Up 10.0%

Shares of Bavarian Nordic stock traded up $1.00 on Friday, hitting $10.95. The company’s stock had a trading volume of 24,514 shares, compared to its average volume of 3,212. The firm has a fifty day moving average price of $9.27 and a 200-day moving average price of $9.68. Bavarian Nordic has a 52-week low of $8.67 and a 52-week high of $13.00. The company has a market capitalization of $2.60 billion, a P/E ratio of 14.41 and a beta of 1.20.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.